title: New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.
abstract: Recent discoveries that non-small cell lung cancer (NSCLC) can be divided into molecular subtypes based on the presence or absence of driver mutations have revolutionized the treatment of many patients with advanced disease. However, despite these advances, a majority of patients are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and prolonged survival. In this article, we review the current status of attempts to target the epigenome, heritable modifications of DNA, histones, and chromatin that may act to modulate gene expression independently of DNA coding alterations, in NSCLC and the potential for combinatorial and sequential treatment strategies.
authors.affiliation: Authors' Affiliation: Upper Aerodigestive Malignancies Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Forde
authors.forename: Julie R
authors.initials: JR
authors.lastname: Brahmer
authors.forename: Ronan J
authors.initials: RJ
authors.lastname: Kelly
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D044127:Epigenesis, Genetic / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D058990:Molecular Targeted Therapy; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents